VolitionRX Ltd. (VNRX) CEO Cameron Reynolds on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Seeking Alpha
VolitionRX Ltd. (NYSEMKT: VNRX ) Q3 2018 Earnings Conference Call November 8, 2018 8:30 AM ET Executives Scott Powell - EVP, IR Cameron Reynolds - President & CEO Analysts Jason McCarthy - Maxim Group Jonas Peciulis - Edison Investment Research Bruce Jackson - The Benchmark Company Brian Marckx - Zacks Investment Research Jay Albany - SeeThruEquity Research Operator Welcome to VolitionRx Limited Third Quarter 2018 Earnings and Business Update Conference Call. [Operator Instructions]. I’d now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead, sir. Scott Powell Thank you, and welcome, everyone, to today’s earnings conference call for VolitionRx Limited. Following our prepared remarks, we will open the conference call to a question-and-answer session. Before we begin, I’d like to remind everyone that some of the information discussed on this conference call will include forward
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Antech's Breakthrough AI-powered Radiology and Targeted Cancer Screening Tools Now Available, Unleashing New Chapter for Veterinary Diagnostics [Yahoo! Finance]Yahoo! Finance
- VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (NYSE: VNRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $2.50 price target on the stock.MarketBeat
VNRX
Earnings
- 11/14/23 - Beat
VNRX
Sec Filings
- 3/26/24 - Form D
- 3/25/24 - Form 10-K
- 3/25/24 - Form 8-K
- VNRX's page on the SEC website